Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29229419 | 1.00 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2TSHRGAANPC1 | |
| SCHEMBL339284 | 1.00 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2TSHRGAANPC1 | |
| SCHEMBL31097913 | 1.00 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2TSHRGAANPC1 | |
| SCHEMBL2695436 | 1.00 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2TSHRGAANPC1 | |
| Water SCHEMBL6653863 | 0.98 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2TSHRGAANPC1 | |
| SCHEMBL27510642 | 0.90 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2TSHRGAANPC1 | |
| SCHEMBL3615410 | 0.87 | CA2 (0.48) | ALDH1A1SMN1; SMN2TSHRNPC1RAB9A | |
| SCHEMBL71815 | 0.81 | CYP2C9 (0.61) | ALDH1A1SMN1; SMN2TSHRGAANPC1 | |
| SCHEMBL11529757 | 0.81 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2TSHRGAANPC1 | |
| SCHEMBL2207056 | 0.81 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2TSHRGAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400505-A1 | (+)-3-(2,3-DIFLUOROPHENYL)-3-METHOXYPYRROLIDINE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, A PROCESS FOR PREPARATION THEREOF AND USES THEREOF | INTEGRATIVE RES LABORATORIES SWEDEN AB (SE) | 2024-12-05 | — | — | US | disclosed |
| CN-110621659-B | (+) -3- (2,3-difluorophenyl) -3-methoxy pyrrolidine or pharmaceutically acceptable salt thereof, preparation method and application thereof | 综合研究实验室瑞典股份公司 | 2023-02-28 | — | — | CN | disclosed |
| US-20120108607-A1 | OPTICALLY ACTIVE 3-[(PHENYLPIPERAZIN-1-YL)ALKYL]-3- ALKYL-OXINDOLE DERIVATIVES HAVING CNS ACTIVITY | EGIS GYOGYSZERGYAR NYILVANOSAN MUEKOEDOE RESZVENYTARSASAG (HU) | 2012-05-03 | — | — | US | disclosed |
| EP-0703221-B1 | 5 alpha-reductase Inhibitors | LILLY CO ELI (US) | 2002-03-27 | — | — | EP | disclosed |
| US-6150375-A | INHIBITORS OF BOTH OF THE HUMAN 5AR ISOZYMES; BENIGN PROSTATE HYPERPLASIA, MALE PATTERN BALDNESS, ACNE VULGARIS, SEBORRHEA, ANDROGENIC ALOPECIA, HIRSUTISM AND PROSTATE CANCER; BLOCKS THE CONVERSION OF TESTOSTERONE TO 5-ALPHA-DIHYDROTESTOSTERONE | ELI LILLY AND COMPANY (US) | 2000-11-21 | — | — | US | disclosed |
| US-5670514-A | BENZOQUINOLIN-3-ONE | ELI LILLY AND COMPANY (US) | 1997-09-23 | — | — | US | disclosed |
| US-5635197-A | BENZO(F)QUINOLIN-3-ONES; ANTICARCINOGENIC AGENTS; BONE DISORDERS | ELI LILLY AND COMPANY (US) | 1997-06-03 | — | — | US | disclosed |
| US-5629007-A | USING BENZOQUINOLIN-3-ONE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1997-05-13 | — | — | US | disclosed |
| US-5622961-A | PROSTATE CANCER, SKIN DISORDERS, BALDNESS | ELI LILLY AND COMPANY (US) | 1997-04-22 | — | — | US | disclosed |
| US-5622962-A | PROSTATE CANCER, SKIN DISORDERS, BALDNESS | ELI LILLY AND COMPANY (US) | 1997-04-22 | — | — | US | disclosed |
| US-5578724-A | INHIBITORS OF 5-ALPHA-REDUCTASE | ELI LILLY AND COMPANY (US) | 1996-11-26 | — | — | US | disclosed |
| WO-1996035422-A1 | METHODS FOR INHIBITING BONE LOSS | ELI LILLY AND COMPANY (US) | 1996-11-14 | — | — | WO | disclosed |
| EP-0742010-A2 | Benzoquinolin-3-ones to inhibit bone loss | ELI LILLY AND COMPANY (US) | 1996-11-13 | — | — | EP | disclosed |
| EP-0733365-A2 | Use of benzoquinolin-3-ones for the treatment and prevention of prostatic cancer | ELI LILLY AND COMPANY (US) | 1996-09-25 | — | — | EP | disclosed |
| US-5550134-A | ADMINISTERING TO A MAMMAL FROM A SERIES OF BENZOQUINOLIN-3-ONE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1996-08-27 | — | — | US | disclosed |
| WO-1996009046-A1 | 5α-REDUCTASE INHIBITORS | ELI LILLY AND COMPANY (US) | 1996-03-28 | — | — | WO | disclosed |
| EP-0703221-A1 | 5 alpha-reductase Inhibitors | ELI LILLY AND COMPANY (US) | 1996-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108607-A1 | OPTICALLY ACTIVE 3-[(PHENYLPIPERAZIN-1-YL)ALKYL]-3- ALKYL-OXINDOLE DERIVATIVES HAVING CNS ACTIVITY | TPH2, OPRK1, CYP3A7 | ALDH1A1 204/4885SMN1; SMN2 155/4885TSHR 1489/4885 |
| US-20240400505-A1 | (+)-3-(2,3-DIFLUOROPHENYL)-3-METHOXYPYRROLIDINE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, A PROCESS FOR PREPARATION THEREOF AND USES THEREOF | FIP1L1, CYP2C9, QDPR | ALDH1A1 443/4885SMN1; SMN2 317/4885TSHR 3951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.